Evaluation of Bone Metastasis Using Serial Measurements of Serum N-Telopeptides of Type I Collagen in Patients with Lung Cancer: A Prospective Study.

Abstract

BACKGROUND/AIM:

The bone resorption biomarker cross-linked N-Telopeptides of type I collagen (NTx) has been shown to aid in the diagnosis of metastatic bone disease from lung cancer (MBDLC). Patients with MBDLC are often treated with zoledronic acid (ZA). ZA reduces the levels of NTx and also lowers the risk of skeletal adverse events in patients with MBDLC.

PATIENTS AND METHODS:

Patients with MBDLC at initial diagnosis were included in the study. NTx was measured in serum (sNTx) once a month using the OSTEOMARKTM sNTx assay. MBDLC was assessed by monthly physical examinations and bone scintigraphy every 3 months for 12 months.

RESULTS:

Twenty patients were enrolled between June and December 2010. The sNTx concentration at baseline was 19.8 ± 5.8 nmol bone collagen equivalents (nmol BCE)/l. In the 16 patients receiving ZA, the level of sNTx significantly decreased after the first month of treatment (baseline vs. 1 month of treatment: 21.3 ± 5.5 vs. 13.6 ± 2.7 nmol BCE/l; p<0.01). During the follow-up period, 13 of the patients treated with ZA experienced worsening of bone metastasis. There were statistically significant differences in the levels of sNTx at baseline (20.3 ± 4.8 nmol BCE/l), at the lowest levels after administration of ZA (11.8 ± 2.9 nmol BCE/l vs. baseline; p<0.001), and at the time of measurable disease progression (14.1 ± 4.6 nM BCE/l vs. baseline; p<0.05).

CONCLUSION:

Serial measurements of sNTx in patients with MBDLC treated with ZA may effectively predict disease progression.

• Authors: Motohiro Tamiya, Shinya Tokunaga, Hideaki Okada, Hidekazu Suzuki, Shinji Sasada, Norio Okamoto, Naoko Morishita, Takayuki Shiroyama, Tomoyuki Otsuka, Natsuko Miyamoto, Koichi Taira, Haruko Daga, Koji Takeda, Tomonori Hirashima
• Journal: Anticancer research (Anticancer Res) Vol. 35 Issue 7 Pg. 3987-93 (Jul 2015) ISSN: 1791-7530 [Electronic] Greece
• PMID: 26124346 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
• Copyright: Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Chemical References

• Collagen Type I
• Diphosphonates
• Imidazoles
• Peptides
• collagen type I trimeric cross-linked peptide
• Zoledronic Acid

Topics

• Adult
• Aged
• Bone Neoplasms (blood, pathology)
• Collagen Type I (blood)
• Diphosphonates (therapeutic use)
• Disease Progression
• Female
• Humans
• Imidazoles (therapeutic use)
• Lung Neoplasms (blood, drug therapy, pathology)
• Male
• Middle Aged
• Peptides (blood)
• Prospective Studies
• Zoledronic Acid